middle.news
Chimeric Therapeutics Advances CAR-T Trial with Tumour Shrinkage and Strategic Review
3:03pm on Friday 31st of July, 2026 AEST
•
Healthcare
Read Story
Chimeric Therapeutics Advances CAR-T Trial with Tumour Shrinkage and Strategic Review
3:03pm on Friday 31st of July, 2026 AEST
Key Points
Positive interim data shows tumour shrinkage up to 40%
60% complete response rate in AML Phase 1B trial
Completed 1-for-100 capital consolidation
Cash balance of $0.8 million at June 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Chimeric Therapeutics (ASX:CHM)
OPEN ARTICLE